AnaptysBio Inc - Company Profile
Powered by 
All the data and insights you need on AnaptysBio Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date AnaptysBio Inc Strategy Report
- Understand AnaptysBio Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
The following section provides information on AnaptysBio Inc’s senior management, executives, CEO and key decision makers and their roles in the organization. For more insight into AnaptysBio Inc's management and employees, unlock the full data with our company analytics monitoring tool.
Executives
John Orwin
Chairman Executive BoardDr. John Orwin has been the Chairman of the company since 2024. Prior to this, he served on the Board of Directors of Array BioPharma, Inc. Previously, he served as the Chief Executive Officer of Relypsa. Currently, he also serves as a Director of Seagen, Inc. and President and Chief Executive Officer of Atreca, Inc.
Daniel Faga
Chief Executive Officer; Director; President - Interim Executive BoardMr. Daniel Faga has been the Interim President and Chief Executive Officer since 2022. Prior to this, he served as Chief Operating Officer at Mirati Therapeutics from 2020 to 2021. Previously, he worked as Chief Business Officer for Spark Therapeutics Inc from 2016 to 2019. Mr. Faga served as Managing Director at Centerview Partners from 2009 to 2016.
Dennis Mulroy
Chief Financial Officer Senior ManagementMr. Dennis Mulroy has been the Chief Financial Officer of the company since July 2020. Prior to this, he served as the Chief Financial Officer of Taxus Cardium Pharmaceuticals Group, Molecular Imaging and SeraCare Life Sciences.
Eric Loumeau
Chief Legal Officer Senior ManagementMr. Eric Loumeau is the Chief Legal Officer of the company. Prior to this role, he served as the Chief Operating Officer, General Counsel and has also served as Interim Chief Financial Officer in the company. Mr. Loumeau served as General Counsel and Chief Compliance Officer at Otonomy, Chief Financial Officer of Rempex Pharmaceutics and General Counsel at Hollis-Eden Pharmaceuticals.
Paul F. Lizzul, M.D., Ph.D
Chief Medical Officer Senior ManagementDr. Lizzul has been the Chief Medical Officer of the company since 2020. Prior to this, he served as the Global Development Head for Inflammation at Amgen. Previously, he served as the Chief Medical Officer of Sienna Biopharmaceuticals and Senior Medical Director of Kythera Biopharmaceuticals.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer